Preview of coming attractions
This thankfully is an off-week earnings wise as next week we have the insulin pump trifecta. Medtronic on the 20th, Tandem the 21st and Insulet the 22nd. This trio effectively encompasses the entire insulin pump market, and each has their own unique set of problems they are facing. So, let’s take them in order of calls starting with Medtronic.
It really should shock no one that Medtronic’s biggest problem is being Medtronic. The 780G is actually a very good AID system but the company continues to shoot themselves in the foot. They can’t seem to find . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.